Annexon posts results for completed Phase 2a ANX005 study in Huntington's disease

Annexon had one Huntington's disease item update this week, with results posted for a completed early-stage trial.

• ANX005, an intravenous drug tested in a Phase 2 open-label study titled "A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease"¹, had results first posted on 2026-08-25. The study, sponsored by Annexon, Inc., enrolled 28 participants¹ and reached primary completion on 2022-08-29 (actual). The primary outcome measured was the number of participants with treatment-emergent adverse events, tracked from first dose through the end of study at Week 36¹.